Recurrent hypoglycemia triggered by sorafenib therapy in a patient with hemangiopericytomaopen access
- Authors
- Lee, Si Won; Lee, Eun Kyung; Yun, Tak; Won, Young-Woong; Ko, Eun Jeong; Choi, Mihong; Choi, Sang Il; Park, Sun Seob; Hong, Eun Kyung
- Issue Date
- Jun-2014
- Publisher
- Korean Endocrine Society
- Keywords
- Hemangiopericytoma; Hypoglycemia; Sorafenib
- Citation
- Endocrinology and Metabolism, v.29, no.2, pp.202 - 205
- Indexed
- SCOPUS
KCI
- Journal Title
- Endocrinology and Metabolism
- Volume
- 29
- Number
- 2
- Start Page
- 202
- End Page
- 205
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159811
- DOI
- 10.3803/EnM.2014.29.2.202
- ISSN
- 2093-596X
- Abstract
- Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of a patient who exhibited a wax and wane pattern of hypoglycemia that was attributed to sorafenib therapy. A 32-year-old woman with metastatic hemangiopericytoma visited the emergency department in a stuporous state. Nonhyperinsulinemic hypoglycemia was diagnosed, was exacerbated shortly after sorafenib therapy, and was improved by the cessation of sorafenib with additional glucocorticoid therapy. Patients with metastatic hemangiopericytoma should be carefully monitored with particular attention to hypoglycemia when sorafenib therapy is initiated.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159811)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.